May 01, 2025 a 01:00 pm
LLY: Fundamental Ratio Analysis - Eli Lilly and Company
Eli Lilly and Company has shown a steady trend in the pharmaceutical sector, specializing in human pharmaceuticals with a broad worldwide reach. With its innovative approaches and collaborations, the company continues to position itself as a leader in its industry.
Fundamental Rating
The fundamental scores reflect Eli Lilly's strong performance in returns and some areas that need attention, such as its debt-to-equity and valuation measures.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
Comparison of the latest and historical ratings showcases consistent performance and evaluation metrics with steady overall scores over time.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-30 | 3 | 3 | 5 | 5 | 1 | 1 | 1 |
| Historically | 0 | 3 | 5 | 5 | 1 | 1 | 1 |
Analyst Targets
Analysts provide a positive outlook on Eli Lilly's price movement with a median target reflective of strong investor confidence.
| High | Low | Median | Consensus |
|---|---|---|---|
| 1146 | 700 | 960 | 941.5 |
Analysts' Sentiment
The majority of analysts recommend buying, indicating bullish sentiment towards Eli Lilly in the market.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 31 | |
| Hold | 7 | |
| Sell | 3 | |
| Strong Sell | 0 |
Conclusion
Eli Lilly exhibits robust growth potential supported by its innovative portfolio and strategic collaborations. Despite certain areas that warrant watching, such as debt levels, the company's overall financial health and market position signify optimistic future performance. Analyst ratings are predominantly favorable, reinforcing confidence among investors. While management's strategic initiatives unfold, upcoming revenues will be critical to monitoring. Investors should consider market conditions that might affect future valuations.